Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis

Clinical and Experimental Immunology

Volumn 143, Issue 1, 2006, Pages 110-116

  Xiaoyan, Zhao ^a   Pirskanen, R ^a   Malmstrom, V ^a   Lefvert, A K ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune disease; CD4+ T cell; Hyperplasia; Myasthenia gravis; OX40 (CD134)

Indexed keywords

CD134 ANTIGEN; CD3 ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; TNFRSF4 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; MYASTHENIA GRAVIS; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THYMUS HYPERPLASIA; CASE CONTROL STUDY; FLOW CYTOMETRY; IMMUNOLOGY; NONPARAMETRIC TEST;

ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MYASTHENIA GRAVIS; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC;

EID: 33644819034     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02955.x     Document Type: Article

References (45)

1. Lennon VA Lindstrom JM Seybold ME Experimental autoimmune myasthenia gravis: cellular and humoral immune responses Ann NY Acad Sci 1976 274 283 99
2. Hohlfeld R Kalies I Kohleisen B Heininger K Conti-Tronconi B Toyka KV Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines Neurology 1986 36 618 21
3. Wang XB Kakoulidou M Giscombe R Qiu Q Huang D Pirskanen R Lefvert AK Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence J Neuroimmunol 2002 130 224 32
4. McIntosh KR Linsley PS Bacha PA Bacha PA Drachman DB Immunotherapy of experimental autoimmune myasthenia gravis. selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein J Neuroimmunol 1998 87 136 46
5. Croft M Costimulation of T cells by OX40, 4-1BB, and CD27 Cytokine Growth Factor Rev 2003 14 265 73
6. Im SH Barchan D Maiti PK Fuchs S Souroujon MC Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4 J Immunol 2001 166 6893 8
7. Ohshima Y Yang LP Uchiyama T Tanaka Y Baum P Sergerie M Hermann P Delespesse G OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors Blood 1998 92 3338 45
8. Rogers PR Song J Gramaglia I Killeen N Croft M OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells Immunity 2001 15 445 55
9. Weatherill AR Maxwell JR Takahashi C Weinberg AD Vella AT OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo Cell Immunol 2001 209 63 75
10. Kawamata S Hori T Imura A Takaori-Kondo A Uchiyama T Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF)2- and TRAF5-mediated NF-kappaB activation J Biol Chem 1998 273 5808 14
11. Akiba H Oshima H Takeda K et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells J Immunol 1999 162 7058 66
12. Stuber E Neurath M Calderhead D Fell HP Strober W Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells Immunity 1995 2 507 21
13. Ohshima Y Tanaka Y Tozawa H Takahashi Y Maliszewski C Delespesse G Expression and function of OX40 ligand on human dendritic cells J Immunol 1997 159 3838 48
14. Stuber E Strober W The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response J Exp Med 1996 183 979 89
15. Murata K Ishii N Takano H Miura S Ndhlovu LC Nose M Noda T Sugamura K Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand J Exp Med 2000 191 365 74
16. Chen AI McAdam AJ Buhlmann JE et al. OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions Immunity 1999 11 689 98
17. Bansal-Pakala P Jember AG Croft M Signaling through OX40 (CD134) breaks peripheral T-cell tolerance Nat Med 2001 7 907 12
18. Lathrop SK Huddleston CA Dullforce PA Montfort MJ WeinbergAD, Parker DC. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions J Immunol 2004 172 6735 43
19. Murata K Nose M Ndhlovu LC Sato T Sugamura K Ishii N Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases J Immunol 2002 169 4628 36
20. Ndhlovu LC Ishii N Murata K et al. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis J Immunol 2001 167 2991 9
21. Weinberg AD Wegmann KW Funatake C et al. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis J Immunol 1999 162 1818 26
22. Wang X Ria M Kelmenson PM Eriksson P et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility Nat Genet 2005 365 8
23. Higgins LM McDonald SA Whittle N Crockett N Shields JG MacDonald TT Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein J Immunol 1999 162 486 93
24. Aten J Roos A Claessen N Schilder-Tol EJ Ten Berge IJ Weening JJ Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis J Am Soc Nephrol 2000 11 1426 38
25. Yoshioka T Nakajima A Akiba H Ishiwata T Asano G Yoshino S Yagita H Okumura K Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis Eur J Immunol 2000 30 2815 23
26. Souza HS Elia CC Spencer J MacDonald TT Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease Gut 1999 45 856 63
27. Tateyama M Fujihara K Ishii N Sugamura K Onodera Y Itoyama Y Expression of OX40 in muscles of polymyositis and granulomatous myopathy J Neurol Sci 2002 194 29 34
28. Kotani A Ishikawa T Matsumura Y Ichinohe T Ohno H Hori T Uchiyama T Correlation of peripheral blood OX40+ (CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation Blood 2001 98 3162 4e
29. Nohar C Akiba H Nakajima A et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells J Immunol 2001 166 2108 15
30. Martin-Orozco N Chen Z Poirot L et al. Paradoxical dampening of anti-islet self-reactivity but promotion of diabetes by OX40 ligand J Immunol 2003 171 6954 60
31. Jember AG Zuberi R Liu FT Croft M Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40 J Exp Med 2001 193 387 92
32. Blazar BR Sharpe AH Chen AI et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients Blood 2003 101 3741 8
33. Onodera J Nagata T Fujihara K Ohuchi M Ishii N Sugamura K Itoyama Y Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus Acta Neurol Scand 2000 102 236 43
34. Oosterhuis HJ The natural course of myasthenia gravis: a long term follow up study J Neurol Neurosurg Psychiatry 1989 52 1121 7
35. Lefvert AK Bergstrom K Matell G Osterman PO Pirskanen R Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications J Neurol Neurosurg Psychiatry 1978 41 394 403
36. Giacomelli R Passacantando A Perricone Parzanese I Rascente M Minisola G Tonietti G T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen Clin Exp Rheumatol 2001 19 317 20
37. Stuber E Buschenfeld A Luttges J Von Freier A Arendt T Folsch UR The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis) Eur J Clin Invest 2000 30 594 9
38. Kotani A Takahashi A Koga H et al. Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells Eur J Haematol 2002 69 318 20
39. Streeter PR Zhang X Tittle TV Schon CN Weinberg AD Maziarz RT CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease Biol Blood Marrow Transplant 2004 10 298 309
40. Teleshova N Matusevicius D Kivisakk P Mustafa M Pirskanen R Link H Altered expression of costimulatory molecules in myasthenia gravis Muscle Nerve 2000 23 946 53
41. Moulian N Bidault J Truffault F Yamamoto AM Levasseur P Berrih-Aknin S Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody Blood 1997 89 3287 95
42. Kuchroo VK Das MP Brown JA B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy Cell 1995 80 707 18
43. Walunas TL Lenschow DJ Bakker CY Linsley PS Freeman GJ Green JM Thompson CB Bluestone JA CTLA-4 can function as a negative regulator of T cell activation Immunity 1994 1 405 13
44. Ju ST Panka DJ Cui H Ettinger R el-Khatib M Sherr DH Stanger BZ Marshak-Rothstein A Fas (CD95) /FasL interactions required for programmed cell death after T-cell activation Nature 1995 373 444 8
45. Cao D Malmstrom V Baecher-Allan C Hafler D Klareskog L Trollmo C Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis Eur J Immunol 2003 33 215 23